Switching Reversibility to Irreversibility in Glycogen Synthase Kinase 3 Inhibitors: Clues for Specific Design of New Compounds
Daniel I. Pérez(Cedars-Sinai Medical Center), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Pablo D. Dans(Institut Pasteur de Montevideo), F. Javier Luque(Universidad Complutense de Madrid), Carmen Gil(Instituto de Salud Carlos III), Santiago Conde(Consejo Superior de Investigaciones Científicas), Concepción Pérez(Instituto de Química Médica)
Cited by 73
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293